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Background Ischaemia in different arterial territories before acutemyocardial infarction (AMI)may influencepost-AMIoutcomes.No
studies have evaluated prospectively collected information on ischaemia and its effect on short- and long-term coronary
mortality. The objective of this study was to compare patients with and without prospectively measured ischaemic pre-
sentations before AMI in terms of infarct characteristics and coronary mortality.
Methods
and results
As part of the CALIBER programme, we linked data from primary care, hospital admissions, the national acute coronary
syndrome registry and cause-specific mortality to identify patients with first AMI (n ¼ 16,439). We analysed time from
AMI tocoronarymortality (n ¼ 5283deaths) usingCoxregression (median2.6 years follow-up), comparingpatientswith
andwithout recent ischaemicpresentations. Patientswith ischaemicpresentations in the90daysbeforeAMIexperienced
lower coronary mortality in the first 7 days after AMI compared with those with no prior ischaemic presentations, after
adjusting for age, sex, smoking, diabetes, blood pressure and cardiovascular medications [HR: 0.64 (95% CI: 0.57–0.73)
P, 0.001], but subsequentmortalitywas higher [HR: 1.42 (1.13–1.77)P ¼ 0.001]. Patientswith ischaemic presentations
closer in time to AMI had the lowest seven day mortality (P-trend ¼ 0.001).
Conclusion In thefirst largeprospective studyof ischaemic presentations prior toAMI,wehave shown that thoseoccurring closest to
AMI are associated with lower short-term coronary mortality following AMI, which could represent a natural ischaemic
preconditioning effect, observed in a clinical setting.
Clinical trials
registration
Clinicaltrials.gov identifier NCT01604486.
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Introduction
Roughlyhalf of patientswith acutemyocardial infarctions (AMIs)have
been previously diagnosed with atherosclerotic disease or have
reported chest pain to their physician.1 Myocardial ischaemia
occurring shortly prior to AMI has been associated with smaller
infarct sizes.2–4 This effect has been attributed to ischaemic precon-
ditioning, the phenomenon by which brief episodes of ischaemia
prior to a prolonged ischaemic insult can improve outcomes.5,6
There has also been growing interest in the use of remote ischaemic
* Corresponding author. Tel: +44 2079272837, Fax: +44 02075806987, Email: emily.herrett@lshtm.ac.uk
& The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ .0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal (2014) 35, 2363–2371
doi:10.1093/eurheartj/ehu286
4
preconditioning as an intervention in experimental studies7 and ran-
domized trials to improveoutcomes after coronary interventions.8–10
However, there is also evidence that patients with prior athero-
sclerotic disease diagnoses in one or more arterial territory are
likely to have more advanced atherosclerotic disease and therefore
poorer outcomes.11 The effect of myocardial or remote ischaemia
at different times prior to a first AMI on subsequent coronary mor-
tality is unclear, especially in the longer term(Supplementarymaterial
online, Table S1).3,12–14
No studies have evaluated prospectively collected information on
pre-AMI ischaemia and the effects on short- and long-term coronary
mortality. Using prospective data to define exposure to ischaemia is
important because in experimentalmodels the time courseof ischae-
mia is critical.15 We have identified three other major limitations of
the epidemiological evidence to date. First, previous studies have
been restricted to myocardial ischaemia despite interest in the con-
ditioning effects of remote ischaemia occurring in other arterial
beds.7,9 Second, most previous studies have been in hospitalized
patients only and with further selection criteria (e.g. patients aged
≥75,12 who met screening criteria for trial entry,16 or were able to
provide a clear history of angina3), which means that the extent of is-
chaemic presentations prior toAMI in general populations is unclear.
Third, previous studies have been unable to assess whether the ap-
parent protective effect was confounded by receipt of risk-lowering
medications.
We sought to address these limitations by performing a large, pro-
spective study of the occurrence, timing and associated outcomes of
ischaemic presentations, including atherosclerotic disease in differ-
ent arterial beds and chest pain before non-fatal and fatal AMI,
both in and out of hospital. The first objective was to compare
patients with and without pre-AMI ischaemic presentations in
terms of AMI characteristics including type [ST-elevation MI
(STEMI) and non ST-elevation MI (NSTEMI)] and severity. The
second objective was to examine the association between pre-AMI
ischaemic presentations and short- and long-term coronary mortal-
ity, and the third to determine whether cardiovascular medications
given in response to these ischaemic presentations are associated
with coronary heart disease mortality.
Methods
Study design
The prospectively collected medical records of a cohort of AMI patients
were reviewed to assess the occurrence of chest pain and ischaemic ath-
erosclerotic disease in any arterial bed in the 90 days prior to AMI. Those
with and without these presentations were compared in terms of their
AMI characteristics and subsequent coronary mortality.
Data sources
Aspart of theCALIBER researchprogramme (Cardiovascular disease re-
search using Linked Bespoke studies and Electronic health Records),17
the records of patients in the Myocardial Ischaemia National Audit
Project (MINAP, the national registry of acute coronary syndrome18),
and Hospital Episode Statistics (HES, hospital discharge data set19)
were linked to longitudinal electronic health records from primary care
in the General Practice Research Database (GPRD20) and to Office for
National Statistics (ONS21) cause-specific mortality data (for details,
see Supplementary material online, Table S2). Linkage was performed
by a trusted third party and was based on National Health Service
(NHS) number, date of birth, gender and postcode. Around 40% of the
general practices in GPRD (all English) permitted linkage.22
Definition of acute myocardial infarction
Patients with non-fatal and fatal AMI were identified based on a record in
any one of the four data sources; in MINAP using cardiac markers and
electrocardiogram findings, Read codes in GPRD, ICD-10 codes in
HES and ONS mortality data (full definitions in Supplementary material
online, Table S2). We excluded those with a recorded history of AMI
(n ¼ 6337), under the age of 18 at AMI (n ¼ 2), not registered with the
primary care practice for at least 1 year before AMI (n ¼ 8516), whose
AMIs occurred outside the period where all databases were collecting
data (outside 1 January 2003 to 31 December 2008, n ¼ 23 804), and
patients without any primary care consultations in their record prior to
AMI (n ¼ 12).
Categorization of ischaemia before acute
myocardial infarction
Patients were initially categorized into three groups based on their
pre-AMI experience of ischaemic atherosclerotic disease (coronary,
cerebrovascular, and peripheral arterial disease, see Supplementary ma-
terial online, Table S3) and chest pain, according to the scheme in Figure 1.
Patientswith ‘noprior ischaemic presentations’ hadnoatherosclerotic
disease in their electronic health record and no consultations for chest
pain in the 90 days before AMI. Patients with ‘new ischaemic presenta-
tions’ had either a new atherosclerotic disease diagnosis in the 90 days
before AMI (either first ever diagnosis or diagnosis in a new arterial
bed, e.g. new coronary disease diagnosis in the presence of longer-term
cerebrovascular disease) or a chest pain consultation in the 90 days
before AMI. Patients with ‘existing ischaemic diseases’ had no new ath-
erosclerotic disease diagnoses or chest pain consultations in the 90
days before AMI but had long-standing atherosclerotic disease (.90
days’ duration). The timing of the onset of atherosclerotic disease was
takenas thedateof thefirst code indicatingdisease in thepatient’s record.
In the second part of the analysis, the timing of the closest ischaemic
presentation prior to AMI was split into categories (1–2, 3–7, 8–30,
and 31–90 days before AMI) based on the time periods used in previous
studies of prodromal angina.14,16,23–27
Cardiovascular risk factors and risk-lowering
medication prior to acute myocardial
infarction
Age, sex, ethnicity, deprivation (based on the Index of Multiple Depriv-
ation 2007, a measure of socio-economic status),28 risk factors and
primary care consultation rate were taken from primary care or hospital
records.Risk factors included smoking, hypertension, total serumcholes-
terol, HDL cholesterol, and diabetes (Supplementary material online,
Table S3). Blood pressure lowering, lipid lowering, and antiplatelet medi-
cationprescriptions in the6months prior toAMIweredeterminedbased
on prescriptions issued in primary care and use of these drugs at hospital
admission.
Follow-up after acute myocardial infarction
and primary outcome
Patients with AMI were followed up for a median of 2.6 years (range 0–
7.7 years) after AMI. The primary outcome was coronary heart disease
death (ICD-10 codes I20-I25).
E. Herrett et al.2364
Statistical analysis
Characteristics of MINAP AMI patients in each exposure group were
compared using x2 tests for categorical variables, Kruskal–Wallis tests
for medians, and t-tests for means. Cox regression analysis was used to
compare post-AMI coronary mortality. Tests for proportional hazards
were performed on all models and interactions with time were fitted
where there was non-proportionality. In the first instance, interactions
with time were fitted based on follow-up time categories of 0–7, 8–
30, 31–90, 91 days to 1 year and 1–2 years, which we considered to
be the time points at which the mortality effects may change. The 0–7
day category is approximately concordant with average duration of hos-
pital stay, making it akin to in-hospital mortality, which is an outcome in
the majority of studies of this type. We then combined the time
periods where the effect of previous ischaemic presentations was
similar, based on similar effect measures and assessed using likelihood
ratio tests. Regression analyseswere adjusted for age, sex, cardiovascular
risk factors andmedications.Detailsofpost hoc and sensitivity analyses are
described in the Supplementary material online.
All analyses were performed in Stata version 11. The study details are
registered online at clinicaltrials.gov (NCT01604486, May 2012) and a
time-stamped detailed analytic protocol is available on request.
CALIBER has received ethics approval (ref 09/H0810/16) for creation
of linked pseudoanonymized data encompassing GPRD, HES, MINAP,
and ONS.
Results
Weidentified16 439patientswith firstAMIwhomet all inclusion cri-
teria. Over one-fifth of these patients were fatal AMIwith no hospital
record; 2119 (12.9%) patients presented to their family physician
with new ischaemic presentations (as defined in methods, Figure 1) in
the 90 days before AMI, 8364 (50.9%) had no prior ischaemic presenta-
tions, and 5956 (36.2%) had existing ischaemic diseases with no new
presentations in the90days beforeAMI. Patientswith existing ischae-
mic disease had the highest pre-AMI Framingham risk (for hard cor-
onary endpoints), those with new ischaemic presentations before
AMI had intermediate risk, and thosewith noprior ischaemic presen-
tations had the lowest risk (Table 1, P, 0.001).
Timing of ischaemic presentations before
acute myocardial infarction
Of the 2119 patients who had ischaemic presentations in the 90 days
prior toAMI, 452 (2.7%)patients first presented in the1–2daysprior
to AMI, 405 (2.5%) in 3–7 days, 676 (4.1%) in 8–30 and 586 (3.6%) in
the 31–90days. A full descriptionof thediagnosesmadeduring these
periods is shown in Supplementary material online, Table S4. Chest
pain, stable angina, and coronary disease of unspecified type were
Figure 1 Use of prospectively collected data to categorize patients who subsequently went on to experience acute myocardial infarction
(n ¼ 16 439), according to prior atherosclerotic disease and chest pain consultations. Note: Atherosclerotic disease, defined as myocardial ischae-
mia (stable or unstable angina, percutaneous coronary ischaemia, coronary artery bypass graft), cerebral ischaemia (ischaemic stroke, transient is-
chaemic attack), and new peripheral arterial disease diagnoses including intermittent claudication (Supplementary material online, Table S3). New
ischaemic presentations in patients with established ischaemic disease represent new chest pain in the context of existing cerebrovascular or per-
ipheral arterial disease, or a diagnosis of ischaemic disease in a new arterial territory.
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the most common presentations in the period before AMI both in
patients with and without established atherosclerotic disease.
Myocardial infarction characteristics
Among6695MINAPpatients, thosewhopresentedwith new ischae-
mia in the 90 days before AMI or with existing ischaemic diseases
were more likely to have a NSTEMI compared with patients who
did not present (68.1% and 68.3 vs. 46.4%, respectively, P, 0.001).
Acute myocardial infarction size, measured by peak troponin
values, was lower (P, 0.001) in thosewith new ischaemic presenta-
tions (median 1.3 mg/L, IQR: 0.3–6.9), and in patientswith existing is-
chaemic diseases (1.4 mg/L, 0.3–7.5) compared with those without
prior ischaemic presentations (2.6 mg/L, 0.6–12.8), but systolic
blood pressure was similar in the three groups. The median heart
rate at admission was similar in those with new ischaemic presenta-
tions to thosewithout anypriordiseasebut higher in thosewithexist-
ing ischaemic diseases (Table 2). Both STEMI and NSTEMI patients
who had presented with new ischaemic presentations in the 90
days prior to AMI had smaller infarct sizes than patients who did
not present (Supplementary material online, Table S6).
Post-acutemyocardial infarction coronary
mortality
Crude 1weekmortality rates for patients in eachof the three analytic
groups are described in Figure 2, which shows that patients with new
ischaemic presentations prior toAMI had lowermortality than those
with no prior ischaemic presentations or patients with existing is-
chaemic diseases.
Patients with ischaemic presentations in the 90 days before AMI
had lower coronary mortality in the first 7 days after AMI compared
with patients with no prior ischaemic presentations, even after ad-
justment for age, sex, cardiovascular risk factors and cardiovascular
medication prescriptions in the 6 months before AMI [HR: 0.64
(95% CI: 0.57–0.73), P, 0.001]. This analysis included deaths
prior to and during hospital admission. In this first week after AMI,
there was borderline evidence of an effect of existing ischaemic
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Table 1 Prospectively collected patient characteristics of patients with and without ischaemic presentations in the 90
days before acute myocardial infarction (n5 16 439 acute myocardial infarction)
No new ischaemic
presentations
New ischaemic presentations
in 90 days before AMI
Existing ischaemic
diseasesa
n patients with AMI 8364 2119 5956
Age, median (IQR) 68 (57–79) 72 (61–81) 79 (70–85)
Women, n (%) 3030 (36.2) 803 (37.9) 2652 (44.5)
Most deprived IMD quintile 1603 (19.2) 399 (18.9) 1281 (21.5)
Smoking, n (%)
Non-smoker 1225 (14.6) 282 (13.3) 792 (13.3)
Ex-smoker 4055 (48.5) 1262 (59.6) 3876 (65.1)
Current smoker 2830 (33.8) 554 (26.1) 1186 (19.9)
Unknown 254 (3) 21 (1) 102 (1.7)
Hypertension, n (%) 3725 (44.5) 1264 (59.7) 4320 (72.5)
Total serum cholesterol in mmol/L, mean (SD) 5.6 (0.8) 5.6 (0.9) 5.3 (1)
HDL cholesterol in mmol/L, mean (SD) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3)
Diabetes, n (%) 1026 (12.3) 377 (17.8) 1505 (25.3)
Framingham 10 year CHD risk, n (%)
,10% 1940 (22.9) 390 (17.7) 639 (11.1)
10–20% 4776 (56.3) 1181 (53.6) 2973 (51.7)
.20% 1763 (20.8) 633 (28.8) 2134 (37.1)
Blood pressure lowering drugs, n (%)
First prescription in 90 days 82 (1) 130 (6.1) 51 (0.9)
Any prescription in 90 days 2,867 (34.3) 1,220 (57.6) 4,261 (71.5)
Lipid-lowering drugs, n (%)
First prescription in 90 days 103 (1.2) 158 (7.5) 132 (2.2)
Any prescription in 90 days 918 (11) 668 (31.5) 2,601 (43.7)
Antiplatelet drugs, n (%)
First prescription in 90 days 79 (0.9) 253 (11.9) 72 (1.2)
Any prescription in 90 days 825 (9.9) 883 (41.7) 3,283 (55.1)
IQR, inter-quartile range; SD, standard deviation; IMD, index of multiple deprivation; HDL, high-density lipoprotein; CHD, coronary heart disease .
aPatients in the ‘existing ischaemic diseases’ group had no new ischaemic presentations in the 90 days prior to AMI.
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diseases on coronary mortality [HR: 0.92 comparedwith no prior is-
chaemic presentations (95% CI: 0.85–1.00) P ¼ 0.05] (Figure 3).
There was no evidence that these associations were modified by
age, sex, previous hypertension, or reperfusion strategy (P.0.05 in
each case). Among all patientswith AMI, the risk of dying before hos-
pitalization was lower for those with new ischaemic presentations
(where the fully adjusted odds ratio for death before hospitalization
in those with new ischaemic presentations was 0.64 (95% CI:
0.55–0.74), P, 0.001 comparedwith thosewith no prior ischaemic
presentations).
During the 7–90 days after AMI, the protective effect seen in the
first week was lost [adjusted HR for new ischaemic presentations
0.88 (95% CI: 0.65–1.20), P ¼ 0.421]. For patients with existing is-
chaemic diseases, this time period sawan increase in the rate ofmor-
tality [adjusted HR: 1.24 (1.01–1.51), P ¼ 0.038] (Figure 3). From 90
days after AMI, there was evidence for higher mortality risk in those
with new ischaemic presentations prior to AMI [adjusted HR: 1.42
(95% CI: 1.13–1.77) P ¼ 0.001]. There was also a stronger effect of
existing ischaemic diseases during this period [adjusted HR: 2.24
(95% CI: 1.91–2.64) P, 0.001].
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Table 2 Myocardial infarction characteristics among acute myocardial infarction patients recorded in the MINAP
registry, in those with and without ischaemic presentations in the 90 days before acute myocardial infarction (n5 6695)
No prior ischaemic
presentations
New ischaemic presentations
in 90 days before AMI
Existing ischaemic
diseasesa
n AMI 3796 681 2218
AMI type, n (%)
STEMI 2192 (57.7) 257 (37.7)*** 786 (35.4)***
NSTEMI 1604 (42.3) 424 (62.3) 1432 (64.6)
ECG record, n (%)
ST segment elevation 2094 (55.2) 237 (34.8)*** 719 (32.4)***
Left bundle branch block 91 (2.4) 23 (3.4) 134 (6)
ST segment depression 385 (10.1) 110 (16.2) 414 (18.7)
T-wave changes only 437 (11.5) 97 (14.2) 283 (12.8)
other abnormality 288 (7.6) 79 (11.6) 283 (12.8)
Normal ECG 209 (5.5) 45 (6.6) 139 (6.3)
Unknown 292 (7.7) 90 (13.2) 246 (11.1)
Peak troponin in mg/L, median (IQR) 2.6 (0.6–13) 1.3 (0.3–6.9)*** 1.4 (0.3–7.5)***
Unknown, n (%) 655 (17.3) 85 (12.5) 261 (11.8)
Raised markers, n (%) 3408 (89.8) 610 (89.6) 2006 (90.4)
Unknown, n (%) 388 (10.2) 71 (10.4) 212 (9.6)
Heart rate at admission (b.p.m.),
median (IQR)
77 (64–91) 77 (65–90) 80 (68–98)***
Unknown, n (%) 857 (22.6) 156 (22.9) 487 (22)
Systolic BP at admission (mmHg),
median (IQR)
140 (122–160) 138 (122–157) 140 (120–159)
Unknown, n (%) 861 (22.7) 158 (23.2) 481 (21.7)
Reperfusion, n (%)
Thrombolysis 1662 (43.8) 180 (26.4)*** 526 (23.7)***
PCI or CABG 274 (7.2) 23 (3.4)*** 88 (4)***
Reperfusion NOS 10 (0.5) 1 (0.2) 5 (0.3)
Time toadmission inminutes,median (IQR) 144.2 (80.8–360.4) 175.9 (89.6–500.3)** 159.5 (85.2–356.1)
Unknown, n (%) 905 (23.8) 235 (34.5) 681 (30.7)
Admission to reperfusion in minutes,
median (IQR)
24 (13.1–50.2) 28.4 (17.5–61.2)** 28.4 (15.3–61.2)***
Unknown, n (%) 1936 (51) 482 (70.8) 1634 (73.7)
Symptom onset to reperfusion in minutes,
median (IQR)
146.4 (96.1–281.8) 172.6 (104.9–345.2)* 170.4 (111.4–290.5)**
Unknown, n (%) 2,166 (57.1) 511 (75) 1704 (76.8)
AMI, acutemyocardial infarction;MINAP,Myocardial IschaemiaNationalAudit Project; STEMI, ST-elevationMI;NSTEMI, non ST-elevationMI; BP, blood pressure; IQR, inter-quartile
range; b.p.m., beats per minute; ECG, electrocardiogram; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NOS, not otherwise specified.
*P, 0.05, **P, 0.01, ***P, 0.001, comparedwith patients with no prior ischaemic presentations, from the x2 test for categorical variables, the Kruskal–Wallis test for comparing
medians, T-test for comparing means.
aPatients in the ‘existing ischaemic diseases’ group had no new ischaemic presentations in the 90 days prior to AMI.
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Figure 2 Crude Kaplan–Meier-based cumulative incidence curves for 7 day coronary heart disease mortality following acute myocardial infarc-
tion (A) in patients with no prior ischaemic presentations (n ¼ 8364), with new ischaemic presentations in the 90 days before acute myocardial in-
farction (n ¼ 2119) and with existing ischaemic diseases (n ¼ 5956), and (B) in patients with no prior ischaemic presentations (n ¼ 8364) and
patients with new ischaemic presentations at different times prior to acute myocardial infarction.
Figure3 Association of new ischaemic presentations and coronary heart diseasemortality at 7 , 7–90, and 90+ days (up to 7.6 years) after acute
myocardial infarction. Note: Hazard ratios are adjusted for age, sex, smoking, hypertension, diabetes, total cholesterol, anti-anginal, blood pressure
lowering, lipid lowering, and antiplatelets in the 6 months before acute myocardial infarction. HR, hazard ratio; AMI, acute myocardial infarction.
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Therewas a strong effect of the timingof clinical presentationprior
to AMI on coronary mortality in the week after AMI (test for trend
P ¼ 0.001). Patients who presented in the 1–2 days before AMI
had the lowest rate of coronary mortality [adjusted HR: 0.53 (95%
CI: 0.40–0.71) P, 0.001], with an intermediate level for those pre-
senting in the 3–7 and 8–30 days before, and with a persistent effect
in patients presenting 31–90 days before AMI [adjusted HR: 0.80
(95% CI: 0.64–0.99) P ¼ 0.042] (Figure 4).
Possible explanations for improved
short-termmortality
Weundertook several post hoc and sensitivity analyses to explain the
results found in the main analysis. These analyses are detailed in the
Supplementary material: in brief we noted that (i) on stratifying our
analysis by AMI type (where available), the effect of new ischaemic
presentations in the 90days prior toAMI on7day coronarymortality
inNSTEMIwas similar to themain effectHR ¼ 0.61 (0.30–1.23), but
the effect in STEMI was 0.83 (0.48–1.41) (P-value for interaction
0.69), though given limited power, the observed differences could
reflect chance variation; (ii) time from symptom onset to hospital
admission and time to reperfusion were longer in the group with
new ischaemic presentations in the 90 days before AMI; (iii) neither
use of cardiovascular medications nor coronary (Framingham) risk
score appeared to confound the observed associations between
prior presentations and mortality, (iv) the protective association
was retained on adjusting for infarct size, but therewere fewpatients
with infarct size recorded and this reduced the power of the analysis
to detect an effect.
Discussion
Summary
The current study provides new insight into the epidemiology of is-
chaemic presentations beforeAMI and their associationswith coron-
arymortality by utilizing prospectively collected data prior to AMI. In
this analysis of fatal and non-fatal AMI patients, those with ischaemic
presentations in the 90 days preceding AMI had a lower rate of cor-
onarymortality in theweek followingAMI comparedwith thosewith
no prior ischaemic presentations. This effect was largest in patients
who consulted in the 2 days before their infarct. Over the following
Figure 4 Association of new ischaemic presentations and coronary heart disease mortality at 7 days after acute myocardial infarction, and the
effect of new ischaemic presentations at different times prior to acute myocardial infarction. aFully adjustedmodel includes age, sex, cardiovascular
disease risk factors, cardiovascular disease medications. Cardiovascular disease risk factors included smoking, hypertension, diabetes, total choles-
terol. Cardiovascular disease medications included anti-anginal, blood pressure lowering, lipid lowering, and antiplatelets in the 6 months before
acute myocardial infarction. HR, hazard ratio; AMI, acute myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular disease.
Association between clinical presentations before myocardial infarction and coronary mortality 2368a
months, the effect transitionedand for patients survivingpast90days,
previous ischaemiawas associatedwith an increased rate of coronary
mortality.We suggest that the early beneficial associations of ischae-
mic presentations in the 2 days prior to AMI with mortality may be a
result of ischaemic preconditioning, and that the later poorermortal-
ity in this group is attributable to a higher atherosclerotic disease
burden.
To our knowledge, no other studies have examined the onset of
atherosclerotic disease or chest pain consultations prospectively in
the period leading toAMI.Other studiesof retrospectivelymeasured
pre-infarction angina have shown that it is associated with fewer
in-hospital outcomes including smaller infarct size3,29 and lower in
hospital coronarymortality3,24 andmore rapid coronary thromboly-
sis,30which is consistentwith our findings. A numberof studies inves-
tigating the effect of remote preconditioning in various settings have
described similar beneficial associations with short- and long-term
non-fatal coronary outcomes.31,32
The current analysis showed that after 90 days of follow-up, the
rate of coronary mortality was higher in the group with ischaemic
presentations compared with those without any presentations.
Thiswasnot explainedbypre-AMI coronary risk,AMI type, orby car-
diovascular medication use prescribed in response to ischaemic pre-
sentations. Other studies investigating longer-term coronary
mortality have shown contradictory results for local ischaemia,
perhaps due to variation in the definition and timing of ischae-
mia,3,24,33 or their methods to examine changes in the effect over
time. Those investigating longer-term outcomes in trials of remote
ischaemic preconditioning have shown beneficial effects on all-cause
and coronary mortality after percutaneous coronary intervention
(PCI)8,10 and coronary artery bypass graft (CABG)32 which is dis-
crepantwith our findings. However, the results of these trials are un-
likely to be concordant with our findings due to the different
exposures (natural ischaemia in the current study vs. inflated blood
pressure cuff in the trials, which is controlled in terms of timing, dur-
ation, and location), different patient populations (all AMI patients in
the current study vs. patients undergoing PCI and CABG32 in the
trials) and different outcomes (coronary mortality here vs. all-cause
mortality in many of the trials). We are unaware of any other studies
investigating the effect of remote and local pre-AMI ischaemia on
longer-term outcomes.
Few studies have investigated the effect of angina at different
times prior to AMI: Kloner et al.34 showed that patients who
reported angina in the 24 h before infarct had a lower event rate
and smaller infarcts, but found no effect of angina occurring
.24 h before infarct. The detail of exposure definition in our
study, the follow-up data on cause and time of death and size of
our study provide sufficient power to clarify the effect of exposures
at different time points on both short- and longer-term coronary
mortality.
Wehaveshownthat theoverall exposureof ischaemia inanyarterial
bed prior to AMI is associated with lower short-term coronary mor-
tality. However, further analysis of our data showed that the effect
was restricted to patients with myocardial ischaemia rather than
with spatially remote ischaemia. The number of patients with non-
myocardial ischaemia in the90 daysprior toAMIwas lowand the asso-
ciations require further consideration given studies showing evidence
for a remote preconditioning effect on post-AMI survival.8,10,32
Possible explanations
Although this study was not designed to investigate mechanisms for
differences in survival, various factors were examined to explain the
observed associations. Similar to another study,25 we found that dif-
ferences in rates of coronary mortality between groups were not
explained by faster time to hospital admission or reperfusion. They
were also not explained by health-seeking behaviour, cardiovascular
medications (despite increased prescriptions in patients with ischae-
mia in the 90 days prior to AMI) or differences in baseline cardiovas-
cular risk.
As described here and elsewhere, previous manifestations of
atherosclerotic disease are associated with NSTEMI rather than
STEMI.1,35,36 However, whether ischaemic symptoms are causally
related to subsequent AMI type, or whether patients with NSTEMI
are simply more likely to experience an intermittent, stuttering
onset of AMI cannot be determined from these data. On stratifying
by AMI type, the effect of ischaemic presentations on 7 day coronary
mortality appeared larger inpatientswithNSTEMI, thoughwedidnot
have enough power among those with known AMI type to exclude
the possibility that this reflected chance variation. The majority of
previous studies have been in STEMI patients and we therefore
suggest that there may also be an effect in NSTEMI.
The associations seen in our analysis may be attributable to a
natural ischaemic preconditioning effect, particularly in the group
presenting in the 1–2 days prior to AMI.37 The associations seen at
times further removed fromAMI (between7 and 90 days) are unlike-
ly to be related to a direct ischaemic preconditioning effect. Instead,
thesemay reflect a continuationof symptomsafter physician consult-
ation, or collateral channel formation.38
The protection against early but not late mortality was also
described in the French Registry of Acute ST-elevation and non-
ST-elevation Myocardial Infarction. In this observational study,
users of the antidiabetic drug glibenclamide, which is used to inhibit
ischaemic preconditioning experimentally, had poorer in hospital
outcomes compared with users of other antidiabetic medications.39
Strengths
This study was in a population-based sample. Inclusion of fatal AMI
patients who did not reach hospital is unique, as other studies drew
their samples from hospitals or trial populations. The prospective
data from primary care allowed detailed measurement of chest
pain and atherosclerotic disease presentations prior to AMI
without errors in recall, and ONS mortality data are near complete
and allowed us to examine long-term follow-up for all patients.
As the gatekeeper for healthcare in theUK, the general practition-
er is likely to see patients with chest pain or ischaemic presentations,
who might then be referred on to a cardiologist or chest pain clinic.
Angina is also managed by the general practitioner in primary care,
and any discharges from secondary care should also be coded in
the general practice record. Therefore, we hope to have captured
the majority of symptoms reported to the healthcare system.
Weaknesses
We are inferring that chest pain or atherosclerotic disease presenta-
tions recorded by GPs are ischaemic, as our measures were not
based on ST segment monitoring or myocardial perfusion imaging.
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We also acknowledge that not all patients with ischaemic symptoms
will report these to a physician, and that many patients will have is-
chaemia in the hours prior to AMI, which our study did not have
the resolution to measure. Indeed, the proportion of patients
who presented with ischaemia here is lower than the reported
proportions in studies that retrospectively assess ischaemia after
AMI.4,14,16 However, any underestimation of ischaemia is unlikely
to account for the observed association; misclassification of patients
who failed to report their symptoms in the days before AMI, or who
had symptoms in the hours before AMI is likely to have led to an
underestimate of the effect of previous ischaemic presentations.
Finally, the timing of the ischaemia exposure in this study reflects
the time when treatment was sought, rather than the true timing of
symptoms. In UK primary care, patients with chest pain should be
seen with little delay, but there may still have been some time lag
into our reported estimates.
Ourprimaryoutcomeof coronaryheart diseasemortalitymaynot
have captured all of the effect of prior ischaemic presentations; there
is increasing evidence to suggest that there may be an effect on non-
coronary mortality.32,40 However, since ours was a study of patients
with AMI, we anticipated that the majority of the effect would be on
coronary outcomes.
Implications
If the lower short-term mortality in those with ischaemic presenta-
tions 1–2 days prior to AMI were due to preconditioning, and the
higher longer-term risk due to more vulnerable disease (and not
causally related to the earlier presentation), then it would suggest
that patients with a suspected AMI and no previously reported
chest pain may warrant more aggressive early treatment, for
example, with aspirin, beta-blockers or thrombolytic drugs, though
such a strategy would need to be properly evaluated in a trial
setting. There may also be implications for the longer-term manage-
ment of patients.
Additionally, there may be a role for intervention with ischaemic
preconditioning. If we had a better understanding of the triggers of
AMI (e.g. influenza41) and were able to identify patients at high short-
term risk of AMI, then an option for intervention might be remote
ischaemic preconditioningwith a blood pressure cuff, shown in rando-
mized trials to be beneficial prior to vascular surgery on subsequent
myocardial damage.9 Research priorities are therefore to investigate
the mechanisms underlying our findings for ischaemic presentations
at various times prior to AMI, to clarify the role of early treatment,
to further investigate potential triggers of AMI and patients at high
short-term risk, and also to characterize the role of AMI type.
Conclusion
In the first large study using prospectively collected information on
ischaemic presentations prior to AMI, symptoms of ischaemia prior
to AMI recorded by a physician are associated with a lower rate of
short term but a higher rate of longer-term coronary mortality.
We observed the strongest associations in patients with ischaemia
closest in time toAMI, but therewas still an effect of ischaemia occur-
ring up to 90 days prior to AMI. These observations are consistent
with a natural ischaemic preconditioning effect, observed in ‘real-
world’ clinical practice.
Supplementary material
Supplementary material is available at European Heart Journal online.
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